EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
Top Cited Papers
- 27 February 2017
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 23 (4) , 483-492
Abstract
Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumor that is located in the pons and primarily affects children. Nearly 80% of DIPGs harbor mutations in histone H3 genes, wherein lysine 27 is substituted with methionine (H3K27M). H3K27M has been shown to inhibit polycomb repressive complex 2 (PRC2), a multiprotein complex responsible for the methylation of H3 at lysine 27 (H3K27me), by binding to its catalytic subunit EZH2. Although DIPGs with the H3K27M mutation show global loss of H3K27me3, several genes retain H3K27me3. Here we describe a mouse model of DIPG in which H3K27M potentiates tumorigenesis. Using this model and primary patient-derived DIPG cell lines, we show that H3K27M-expressing tumors require PRC2 for proliferation. Furthermore, we demonstrate that small-molecule EZH2 inhibitors abolish tumor cell growth through a mechanism that is dependent on the induction of the tumor-suppressor protein p16INK4A. Genome-wide enrichment analyses show that the genes that retain H3K27me3 in H3K27M cells are strong polycomb targets. Furthermore, we find a highly significant overlap between genes that retain H3K27me3 in the DIPG mouse model and in human primary DIPGs expressing H3K27M. Taken together, these results show that residual PRC2 activity is required for the proliferation of H3K27M-expressing DIPGs, and that inhibition of EZH2 is a potential therapeutic strategy for the treatment of these tumors.Keywords
This publication has 42 references indexed in Scilit:
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin LymphomaMolecular Cancer Therapeutics, 2014
- Chromatin proteins and modifications as drug targetsNature, 2013
- An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1ACS Chemical Biology, 2013
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsNature, 2012
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemiaNature Medicine, 2012
- Analysis of the coding genome of diffuse large B-cell lymphomaNature Genetics, 2011
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphomaNature, 2011
- Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disordersNature Genetics, 2010
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center originNature Genetics, 2010
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002